blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3216784

EP3216784 - PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  01.11.2019
Database last updated on 09.07.2024
FormerThe patent has been granted
Status updated on  23.11.2018
FormerGrant of patent is intended
Status updated on  08.08.2018
FormerRequest for examination was made
Status updated on  12.01.2018
FormerThe application has been published
Status updated on  11.08.2017
Most recent event   Tooltip01.11.2019No opposition filed within time limitpublished on 04.12.2019  [2019/49]
Applicant(s)For all designated states
Janssen Pharmaceutica NV
Turnhoutseweg 30
2340 Beerse / BE
[2017/37]
Inventor(s)01 / Broggini, Diego
Armin-bollinger-weg 5
CH-8050 Zürich / CH
02 / Lellek, Vit
Schauenbergstrasse 8
CH-8046 Zürich / CH
03 / Mani, Neelakandha, S.
13109 Russet Leaf Lane
San Diego CA 92129 / US
04 / Lochner, Susanne
Tittisbuehl 1
78224 Singen / DE
05 / Mauer, Adrian
Gemshalde 30
CH-8200 Schaffhausen / CH
06 / Pippel, Daniel, J.
13106 Caminito Mar Villa
Del Mar CA 92014 / US
07 / Young, Lana
9695 Diego Del Vida
San Diego CA 92121 / US
 [2017/37]
Representative(s)Carridge, Andrew Edward
Reddie & Grose LLP The White Chapel Building
10 Whitechapel High Street
London E1 8QS / GB
[2017/37]
Application number, filing date17151754.317.03.2010
[2017/37]
Priority number, dateUS20090161177P18.03.2009         Original published format: US 161177 P
[2017/37]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3216784
Date:13.09.2017
Language:EN
[2017/37]
Type: B1 Patent specification 
No.:EP3216784
Date:26.12.2018
Language:EN
[2018/52]
Search report(s)(Supplementary) European search report - dispatched on:EP07.06.2017
ClassificationIPC:C07D213/82
[2017/37]
CPC:
C07D213/82 (EP,US); C07D405/12 (EP,US); C07B2200/13 (US)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2018/07]
Former [2017/37]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  SM,  TR 
TitleGerman:VERFAHREN ZUR HERSTELLUNG VON HISTAMIN-H3-REZEPTORMODULATOREN[2017/37]
English:PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS[2017/37]
French:PROCÉDÉ DE PRÉPARATION DE MODULATEURS DES RÉCÉPTEURS D'HISTAMINE H3[2017/37]
Examination procedure17.01.2017Date on which the examining division has become responsible
29.12.2017Amendment by applicant (claims and/or description)
29.12.2017Examination requested  [2018/07]
09.08.2018Communication of intention to grant the patent
12.11.2018Fee for grant paid
12.11.2018Fee for publishing/printing paid
12.11.2018Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP10722449.5  / EP2429996
Divisional application(s)EP18194673.2  / EP3492451
Opposition(s)27.09.2019No opposition filed within time limit [2019/49]
Fees paidRenewal fee
17.02.2017Renewal fee patent year 03
17.02.2017Renewal fee patent year 04
17.02.2017Renewal fee patent year 05
17.02.2017Renewal fee patent year 06
17.02.2017Renewal fee patent year 07
17.02.2017Renewal fee patent year 08
29.03.2018Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Licence(s)ID:01 01/exclusive
For:AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
Licencee:BenevolentAI Bio Ltd
40 Churchway
London
NW1 1LW / GB
Date:07.03.2017
[2017/37]
Documents cited:Search[AD]WO2007143422  (JANSSEN PHARMACEUTICA NV [BE], et al) [AD] 1,2 * Scheme B-1;; example 8.c *;
 [ADP]WO2009067401  (JANSSEN PHARMACEUTICA NV [BE], et al) [ADP] 1,2 * Scheme B *;
 [A]  - KALYANAM N. ET AL, "Stereochemistry and conformation of 8-aryl-1,5-diazabicyclo[3.2.1]octanes by 2D NMR studies", JOURNAL OF ORGANIC CHEMISTRY, (19880101), vol. 53, pages 420 - 423, XP002611962 [A] 1,2 * page 422, under experimental section, 8-aryl-1,5-diazabicyclo[3.2.1]octanes *
 [A]  - ANDERSON J.E. ET AL, "NMR study of stereoelectronic anomeric and homoanomeric effects on the axial and equatorial CH bonds in 1,3-diazacyclohexanes and 1,5-diazabicyclo[3.2.1]octanes", JOURNAL OF CHEMICAL SOCIETY, PERKIN TRANS 2, (19970101), no. 12, pages 2633 - 2637, XP002611963 [A] 1,2 * page 2637, under 1,5-diazabicyclo[3.2.1]octane *
by applicantUS2007281923
 US2009131415
    - ARRANG, J.-M. ET AL., "Auto-inhibition of brain histamine release mediated by a novel class (H ) of histamine receptor", NATURE, (1983), vol. 302, doi:doi:10.1038/302832a0, pages 832 - 837, XP001068971

DOI:   http://dx.doi.org/10.1038/302832a0
    - KRAUSE,M. ET AL., The Histamine Ha Receptor-A Target for New Drugs, ELSEVIER, (1998), pages 175 - 196,197-
    - MORISSET, S. ET AL., "High constitutive activity of native H receptors regulates histamine neurons in brain", NATURE, (2000), vol. 408, doi:doi:10.1038/35048583, pages 860 - 864, XP002350695

DOI:   http://dx.doi.org/10.1038/35048583
    - BONAVENTURE, P. ET AL., "Histamine H receptor antagonists: From target identification to drug leads", BIOCHEM. PHARM., (2007), vol. 73, doi:doi:10.1016/j.bcp.2006.10.031, pages 1084 - 1096, XP005932714

DOI:   http://dx.doi.org/10.1016/j.bcp.2006.10.031
    - LETAVIC, M.A. ET AL., "5 Recent Medicinal Chemistry of the Histamine H Receptor", PROA. MED. CHEM., (2006), vol. 44, pages 181 - 206
    - BERGE, S.M. ET AL., "Pharmaceutical Salts", J. PHARM. SCI., (1977), vol. 66, doi:doi:10.1002/jps.2600660104, pages 1 - 19, XP002675560

DOI:   http://dx.doi.org/10.1002/jps.2600660104
    - FLEISHER, D. ET AL., "Improved oral drug delivery: solubility limitations overcome by the use of prodrugs", ADV. DRUG DELIVERY REV., (1996), vol. 19, doi:doi:10.1016/0169-409X(95)00103-E, pages 115 - 130, XP002478093

DOI:   http://dx.doi.org/10.1016/0169-409X(95)00103-E
    - ROBINSON, R.P. ET AL., "Discovery of the hemifumarate and (alpha-L-alanyloxy)methyl ether as prodrugs of an antirheumatic oxindole: prodrugs for the enolic OH group", J. MED. CHEM., (1996), vol. 39, doi:doi:10.1021/jm950575k, pages 10 - 18, XP002152836

DOI:   http://dx.doi.org/10.1021/jm950575k
    - BERTOLINI ET AL., "A new rational hypothesis for the pharmacophore of the active metabolite of leflunomide, a potent immunosuppressive drug", J. MED. CHEM., (1997), vol. 40, doi:doi:10.1021/jm970039n, pages 2011 - 2016, XP002548068

DOI:   http://dx.doi.org/10.1021/jm970039n
    - SHAN ET AL., "Prodrug strategies based on intramolecular cyclization reactions", J. PHARM. SCI., (1997), vol. 86, no. 7, doi:doi:10.1021/js970069d, pages 765 - 767, XP009009562

DOI:   http://dx.doi.org/10.1021/js970069d
    - BAGSHAWE, K.D., "Antibody-directed Enzyme Prodrug Therapy: A Review", DRUG DEV. RES., (1995), vol. 34, doi:doi:10.1002/ddr.430340211, pages 220 - 230, XP000562092

DOI:   http://dx.doi.org/10.1002/ddr.430340211
    - BODOR, N., "Novel Approaches to the Design of Safer Drugs: Soft Drugs and Site-Specific Chemicla Delivery Systems", ADV. DRUG RES., (1984), vol. 13, pages 224 - 331
    - PANULA, P. ET AL., "Significant Changes in the Human Brain Histaminergic System in Alzheimer's Disease", SOC. NEUROSCI. ABSTR., (1995), vol. 21, page 1977
    - BARNES, J.C. ET AL., "The Selective Histamine H3 Receptor Antagonist Thioperamide Improves Cognition and Enhances Hippocampal Acetylcholine Release in vivo", SOC. NEUROSCI, ABSTR., (1993), vol. 19, page 1813
    - MIYAZAKI, S. ET AL., "Effects of thioperamide, a histamine H -receptor antagonist, on a scopolamine-induced learning deficit using an elevated plus-maze test in mice", LIFE SCI., (1995), vol. 57, no. 23, doi:doi:10.1016/0024-3205(95)02206-X, pages 2137 - 2144, XP002269927

DOI:   http://dx.doi.org/10.1016/0024-3205(95)02206-X
    - ORSETTI, M. ET AL., "Histamine H''3-receptor antagonism improves memory retention and reverses the cognitive deficit induced by scopolamine in a two-trial place recognition task", BEHAV. BRAIN RES, (2001), vol. 124, no. 2, pages 235 - 242
    - MIYAZAKI, S. ET AL., "Effects of thioperamide on the cholinergic system and the step-through passive avoidance test in mice", METH. FIND. EXP. CLIN. PHARMACOL., (1995), vol. 17, no. 10, pages 653 - 658
    - CHEN, Z., "Effect of histamine H3-receptor antagonist clobenpropit on spatial memory of radial maze performance in rats", ACTA PHARMACOL. SINICA., (2000), vol. 21, no. 10, pages 905 - 910
    - FOX, G.B. ET AL., "Effects of histamine H''3 receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup", BEHAV. BRAIN RES., (2002), vol. 131, no. 1-2, pages 151 - 161
    - SCHLICKER, E. ET AL., "The moderate affinity of clozapine at H receptors is not shared by its two major metabolites and by structurally related and unrelated atypical neuroleptics", NGUNVN-SCHMIEDEBERG'S ARCH, OF PHARMACOL., (1996), vol. 353, no. 3, pages 290 - 294, XP000901047
    - LAMBERTI, C. ET AL., "Antidepressant-like effects of endogenous histamine and of two histamine H1 receptor agonists in the mouse forced swim test", BR. J. PHARMACOL., (1998), vol. 123, no. 7, doi:doi:10.1038/sj.bjp.0701740, pages 1331 - 1336, XP001064289

DOI:   http://dx.doi.org/10.1038/sj.bjp.0701740
    - PEREZ-GARCIA, C. ET AL., "Effects of Histamine H3 Receptor in Experimental Models of Anxiety and Depression", PSYCHOPHARMACOLOGY, (1999), vol. 142, no. 2, doi:doi:10.1007/s002130050882, pages 215 - 220, XP000980226

DOI:   http://dx.doi.org/10.1007/s002130050882
    - STARK, H. ET AL., "Developments of histamine H -receptor antagonist", DRUGS FUTURE., (1996), vol. 21, no. 5, pages 507 - 520, XP002084872
    - LEURS, R. ET AL., "The medicinal chemistry and therapeutic potentials of ligands of the histamine H receptor", PROP. DRUG RES., (1995), vol. 45, pages 107 - 165
    - YOKOYAMA, H. ET AL., "Effect of thioperamide, a histamine H3 receptor antagonist, on electrically induced convulsions in mice", EUR. J. PHARMACAL., (1993), vol. 234, doi:doi:10.1016/0014-2999(93)90717-V, pages 129 - 133, XP023780199

DOI:   http://dx.doi.org/10.1016/0014-2999(93)90717-V
    - MACHIDORI, H. ET AL., "Zucker obese rats: defect in brain histamine control of feeding", BRAIN RES., (1992), vol. 590, doi:doi:10.1016/0006-8993(92)91093-T, pages 180 - 186, XP024279088

DOI:   http://dx.doi.org/10.1016/0006-8993(92)91093-T
    - The Handbook of Pharmaceutical Excipients, AMERICAN PHARMACEUTICAL ASSOCIATION
    - LIEBERMAN ET AL, Pharmaceutical Dosage Forms: Tablets, vol. 1-3
    - AVIS ET AL, Pharmaceutical Dosage Forms: Parenteral Medications, vol. 1-2
    - LIEBERMAN ET AL, Pharmaceutical Dosage Forms: Disperse Systems, MARCEL DEKKER, INC, vol. 1-2
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.